en · de · es · pt
selank-notes.peptides1004.com › Wiki › Administration, Testing And Availability — Quick Reference

Administration, Testing And Availability — Quick Reference

By Editorial Desk · published 2025-08-21 · last reviewed 2025-09-16 · Wiki

Intranasal route comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2025-09-16. Numbers and descriptions here follow the published literature rather than marketing material.

Administration, Testing and Availability

Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.

Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.

Identity and Structural Background

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.

Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.

Selank at a glance

PropertyValueNotes
Common routeIntranasalAlso injected in some animal work
Solubility classFreely soluble in waterSolid form is hygroscopic
Typical storageAbout -20 degrees CelsiusKeep desiccated and dark
Purity methodReverse-phase HPLCReported as area percent
Confirmatory methodMass spectrometryVerifies expected molecular mass

Analytical Methods and Stability

Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.

Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.

Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.

Related pages on this site

Mechanism and Evidence Base

Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.

Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.

Peptide Identity and Structure

The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.

Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.

Supporting material

. Whenever the integer nature of the number of agents is evident (populations with fewer than tens of thousands of individuals), inherent fluctuations in the disease spreading process caused by discrete agents result in uncertainties. In this scenario, the evolution of the disease predicted by compartmental equations deviates significantly from the observed results. These uncertainties may even cause the epidemic to end earlier than predicted by the compartmental equations. As a special case, one obtains the usual logistic function by assuming

=== February === 2 February – Auckland Transport raises fares on buses, trains and ferries by 5.2% and ends the 10% off-peak discount. 3 February – The Tāhuna Glenorchy area of Central Otago is certified a Dark Sky Sanctuary, the 23rd such designation in the world and fifth in New Zealand. 4 February – 900 private sector laboratory workers strike to protest poor conditions and a lack of pay parity with their public sector counterparts. 5 February: The New Zealand Government confirms it will invest between NZ$100–150 million in upgrading State Highway 76 in Christchurch. It is announced that New Zealand's unemployment rate reaches 5.1%, the highest level since September 2020. Several Māori leaders and attendees protest against several government ministers including David Seymour, Paul Goldsmith and Shane Jones during a pōwhiri leading up to Waitangi Day. Seymour's speech is disrupted while Jones threatens to cut government funding to the Waitangi National Trust. 6 February: Prime Minister Christopher Luxon attends Waitangi Day celebrations at Ngāi Tahu's Ōnuku marae in Akaroa. The town hall in Roxburgh, Otago, which included the country's longest-running cinema, is destroyed by fire. The former building for New Zealand's sole Jewish school "Kadimah School" is vandalised with antisemitic graffiti referencing the Gaza war. 7 February: Health New Zealand chief executive Margie Apa resigns four months before the end of her contract. Taupō experiences heavy showers and thunderstorms, resulting in surface flooding and power outages.

== Biology, medicine and chemistry == Code C08 Calcium channel blockers, in ATC (Anatomical Therapeutic Chemical Classification System) C08, Malignant neoplasm of other and unspecified major salivary glands ICD-10 code C8 complex, three proteins involved in the complement system (part of the immune system) Cervical spinal nerve 8 in human anatomy Carbon-8 (C-8 or 8C), an isotope of carbon An octyl-type hydrocarbon with eight carbon atoms like in a C8 bonded silica stationary phase column, a type of column used in reversed-phase chromatography Perfluorooctanoic acid (PFOA, known colloquially as C8), a ubiquitous chemical used in the production of PTFE

Sources: en.wikipedia.org

Notes from published material

=== Non-medical use === Though not an approved drug, LGD-4033 (Ligandrol) has been sold on the black market as a designer drug in countries where it is classified as an illegal substance. Along with enobosarm (ostarine; GTx-024, S-22), andarine (GTx-007; S-4), and vosilasarm (RAD140; "testolone"), LGD-4033 is one of the most popular and common non-medically-used SARMs. Many products sold online that are purported to be LGD-4033 either contain none or contain other unrelated substances, and doses are also frequently not as labeled. Social media has played an important role in facilitating the widespread non-medical use of SARMs. On 23 October 2017, a nutritional supplement company in Missouri called Infantry Labs was warned by the FDA that the distribution of two of its products violated the Federal Food, Drug, and Cosmetic Act. One of the substances was LGD-4033. The company advertised as benefits of the LGD-4033: "increases in lean body mass and decrease in body fat" and "increases in strength, well being, as well as healing possibilities". The company mislabeled as "dietary supplements" what should have been "new drugs" or "prescription drugs" and were instructed to document the steps they would take in order to cease the violation. Also on 23 October 2017, the FDA sent a warning letter to a New Jersey company called Panther Sports Nutrition. The company's marketing approach for the product was similar to that of the Infantry Labs case, and the product was advertised as a "mass builder" and "physique enhancing agent".

=== Names === Leuprorelin is the generic name of the drug and its INNTooltip International Nonproprietary Name and BANTooltip British Approved Name, while leuprorelin acetate is its BANMTooltip British Approved Name and JANTooltip Japanese Accepted Name, leuprolide acetate is its USANTooltip United States Adopted Name and USPTooltip United States Pharmacopeia, leuprorelina is its DCITTooltip Denominazione Comune Italiana, and leuproréline is its DCFTooltip Dénomination Commune Française. It is also known by its developmental code names A-43818, Abbott-43818, DC-2-269, and TAP-144. Leuprorelin is marketed by Bayer AG under the brand name Viadur, by Tolmar under the brand names Eligard and Fensolvi, and by TAP Pharmaceuticals (1985–2008), by Varian Pharmed( Previously named Varian Darou Pajooh) under the brand name Leupromer and Abbott Laboratories (2008–present) under the brand name Lupron.

Hox genes A subset of highly conserved homeobox-containing genes whose protein products function as transcription factors essential for the proper organization of the body plan in developing animal embryos, ensuring that the correct structures are formed in the correct places. Hox genes are usually arranged on a chromosome in tandem arrays and are expressed sequentially during development, with the sequence of gene activation corresponding to their physical arrangement within the genome and/or the physical layout of the tissues in which they are expressed along the organism's anterior–posterior axis.

Sources: en.wikipedia.org

Frequently asked questions

How is the peptide typically administered in studies?

Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.

What do the human studies show?

Reported human trials are few, brief and originate mainly from one country. They describe effects on anxiety-related measures, but sample sizes are small and reporting is limited. The results are widely regarded as preliminary rather than confirmed.

How is sample identity verified?

Reverse-phase liquid chromatography is used to assess purity and separation of related impurities. Mass spectrometry confirms that the observed molecular mass matches the expected peptide. A certificate of analysis from the supplier is the usual document of record.

What is the peptide sequence of Selank?

The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly written as TKPRPGP. It shares the first four residues with tuftsin and carries three prolines in the chain. The proline-rich tail is the main structural feature that separates it from the parent tetrapeptide.

Network